newsfilter
← Latest News
GlobeNewswire·

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today